Anti-tumor immunity elicited by adenovirus encoding AdhTrp2 or AdmTrp2 without vitiligo

Abstract

To compare the difference in tumor immunity and autoimmunity elicited by adenovirus (Ad) encoding human or murine tyrosinase-related protein 2 (AdhTRP2 or AdmTRP2), and to find the most effective way to induce immunity by AdhTRP2 or AdmTRP2, C57BL/6 mice were immunized with AdhTRP2 or AdmTRP2 intramuscularly at different doses of 10⁵, 10⁶, 10⁷ and 10⁸ separately (10 mice for each dose). Two weeks after the immunization, in vivo CTL assay and intracellular staining (ICS) of IFN-γ were carried out to analyze the dose-effect relationship. Tumor growth and vitiligo (as an sign of autoimmunity) were observed until 3 months after challenge with 10⁵ B16F10 tumor cells. The results showed that Ad encoding AdmTrp2 induced weak tumor immune response. Similar immunization with AdhTrp-2 elicited stronger protective immunity. CTL activity and IFN-γ-produced CD8+T cells were directly proportional to dose of AdhTrp2 or AdmTrp2. Moreover, AdhTrp2 group showed tumor rejection in 100% of challenged mice till the end of 3rd month while 60% of mice immunized with AdmTrp2 were protected against tumor. In the whole process of this experiment, no vitiligo was observed in mice immunized either with AdhTrp2 or AdmTrp2. It is concluded that anti-melanoma responses induced by genetic vaccination expressing xenoantigens breaks immune tolerance effectively and is able to elicit strong antigen-specific cytotoxic T cell response without vitiligo.

Keywords

adenovirus / antigen / tumor immunity / immune tolerance

References

[1] PardollD.. Does the immune system see tumors as foreign or self?. Annu Rev Immunol, 2003, 21: 807-839

[2] MendirattaS. K., ThaiG., EslahiN. K., et al.. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res, 2001, 61(3): 859-863

[3] GoldJ. S., FerroneC. R., Guevara-PatinoJ. A., et al.. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol, 2003, 170(10): 5188-5194

[4] LaneC., LeitchJ., TanX., et al.. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res, 2004, 64(4): 1509-1514

[5] ColesR. M., MuellerS. N., HeathW. R., et al.. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus. J Immunol, 2002, 168(2): 834-838

[6] KarimiK., BoudreauJ. E., FraserK., et al.. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFNgamma-producing NK cells. Mol Ther, 2008, 16(2): 411-418

[7] BadovinacV. P., HartyJ. T.. Intracellular staining for TNF and IFN-γ detects different frequencies of antigen-specific CD8+ T cells. J Immunol Methods, 2000, 238(1–2): 107-117

[8] WeiY. Q., WangQ. R., ZhaoX., et al.. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med, 2000, 6(10): 1160-1166

[9] FurumuraM., SakaiC., PotterfS. B., et al.. Characterization of genes modulated during pheomelanogenesis using differential display. Proc Natl Acad Sci USA, 1998, 95(13): 7374-7378

[10] PardollD. M.. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA, 1999, 96(10): 5340-5342

[11] OverwijkW. W., LeeD. S., SurmanD. R., et al.. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA, 1999, 96(6): 2982-2987

[12] BowneW. B., SrinivasanR., WolchokJ. D., et al.. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med, 1999, 190(11): 1717-1722

[13] NandaN. K., SercarzE. E.. Induction of anti-self-immunity to cure cancer. Cell, 1995, 82(1): 13-17

[14] RosenbergS. A., WhiteD. E.. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol, 1996, 19(1): 81-84

[15] TanX. H., WanY. H.. Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury. Natl Med J (Chinese), 2005, 85(123): 1596-1600